The CCPG1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population with disrupted CCPG1 expression. Generated in the Raji B lymphocyte line, this loss-of-function model provides a uniform background for studying CCPG1-dependent cell cycle control. The polyclonal format captures a diverse range of edits targeting CCPG1, minimizing clonal bias while ensuring robust gene disruption. This ready-to-use product streamlines functional genomics and drug discovery applications without requiring single-cell cloning. This polyclonal knockout population is ideal for high-throughput screens and robust functional assays where clonal heterogeneity is minimized.
The parental Raji line is an EBV-positive Burkitt??s lymphoma model with a mature B cell phenotype. It expresses surface IgM and harbors MYC?Cimmunoglobulin translocations that drive constitutive MYC overexpression. Widely used in B-cell malignancy research, Raji cells exhibit rapid proliferation and aberrant cell cycle progression, offering an ideal host for investigating oncogenic pathways through targeted gene knockout. Their well-characterized genomic landscape and established experimental protocols further facilitate rigorous mechanistic studies.
CCPG1 acts downstream of E2F transcription factors (E2F1, E2F2) to promote G1/S transition and DNA replication. E2F activity is released upon RB1 phosphorylation by cyclin D1?CCDK4, enabling CCPG1 transcription. CCPG1 protein interacts with CDK2/cyclin E and upregulates replication factors including MCM2, PCNA, CDC6, and ORC1. Together with modulators like p21, this network links growth signals to S phase entry in B lymphocytes.
In Raji cells, CCPG1 disruption provides a tractable system to dissect proliferation control in B-cell lymphoma. Because MYC-driven transcription converges on E2F targets, loss of CCPG1 may reveal compensatory pathways or synthetic lethal vulnerabilities. The polyclonal knockout enables robust analysis of cell cycle distribution, DNA synthesis, and target gene expression without clone-specific artifacts, making it suitable for translational lymphoma research.
Typical applications include flow cytometry with PI or BrdU for cell cycle profiling, western blotting for cyclins and CDKs, RT-qPCR for CCPG1 and replication targets, and MTS proliferation assays. Drug screening for anti-mitotic agents and RNA-seq transcriptomics are also readily performed. The polyclonal nature allows straightforward integration into existing laboratory workflows for cancer biology and drug development. For detailed technical information or custom inquiries, please contact Ascent Research.
